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Abstract
Similar to other integrin-targeting strategies, disintegrins have previously shown good efficacy in animal cancer models with
favorable pharmacological attributes and translational potential. Nonetheless, these polypeptides are notoriously difficult to
produce recombinantly due to their particular structure requiring the correct pairing of multiple disulfide bonds for
biological activity. Here, we show that a sequence-engineered disintegrin (called vicrostatin or VCN) can be reliably
produced in large scale amounts directly in the oxidative cytoplasm of Origami B E. coli. Through multiple integrin ligation
(i.e., avb3, avb5, and a5b1), VCN targets both endothelial and cancer cells significantly inhibiting their motility through a
reconstituted basement membrane. Interestingly, in a manner distinct from other integrin ligands but reminiscent of some
ECM-derived endogenous anti-angiogenic fragments previously described in the literature, VCN profoundly disrupts the
actin cytoskeleton of endothelial cells (EC) inducing a rapid disassembly of stress fibers and actin reorganization, ultimately
interfering with EC’s ability to invade and form tubes (tubulogenesis). Moreover, here we show for the first time that the
addition of a disintegrin to tubulogenic EC sandwiched in vitro between two Matrigel layers negatively impacts their survival
despite the presence of abundant haptotactic cues. A liposomal formulation of VCN (LVCN) was further evaluated in vivo in
two animal cancer models with different growth characteristics. Our data demonstrate that LVCN is well tolerated while
exerting a significant delay in tumor growth and an increase in the survival of treated animals. These results can be partially
explained by potent tumor anti-angiogenic and pro-apoptotic effects induced by LVCN.
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Introduction
Despite the tremendous progress made in the last decades in
deciphering the molecular intricacies of various signaling circuit-
ries that operate aberrantly in cancers and the therapeutic
advancement seen with some of the newer anti-cancer modalities
recently approved by the FDA, such as humanized monoclonal
antibodies directed at VEGF-A (vascular endothelial growth factor
A) and receptor tyrosine kinases [1,2] or non-peptide tyrosine
kinase inhibitors [3,4], the 5-year prognosis for most solid tumors
remains reserved. Consequently, there is still a significant need to
identify new drug candidates with broader spectrums of activity
directed at signaling platforms (regulatory molecular hubs) shared
by distinct cancer processes, which are, thus, able to simulta-
neously target multiple pathological aspects of cancer (for instance,
both tumor angiogenesis and metastasis) with fewer side effects.
The ability of transformed cells to evade the restrictive
environmental control exerted by the normal tissue architecture
and grow in an anchorage-independent fashion is one of cancer’s
hallmarks [5]. One class of cell-surface receptors known to play a
critical role in the process leading to the acquisition of an
anchorage-independent phenotype is represented by the integrins
[6].
Integrins are heterodimeric receptors that evolved to mediate
the complex cell-ECM interactions that regulate the ability of cells
to mechanically sense their environment by assembling complex
multimolecular platforms capable of integrating multiple signaling
pathways initiated by extracellular cues with the cellular
cytoskeleton. In the ecology of multicelular organisms integrins
are major contributors to the homeostasis of tissue architecture by
keeping epithelial cells in a differentiated, specialized state [7].
Conversely, as epithelia transition to malignancy they evade the
microenvironmental constraints by both altering their integrin
affinity and avidity for ECM proteins (inside-out signaling) and/or
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played by different integrin subunits in various aspects of tumor
progression and why some integrins appear to be especially
supportive of tumor progression [9] are still not fully understood.
Despite these limitations, due to their pivotal roles in cancer
biology, integrins represent attractive therapeutic targets. For
instance, although it doesn’t seem to be essential for the formation
of vasculature during development [10], nor during physiological
angiogenesis associated with wound healing or tissue repair
[11,12], the b3 integrin appears to be critically involved in the
regulation of pathological angiogenesis [13]. Therefore, the
pharmacological blockade of the b3 integrin has been demon-
strated to significantly reduce tumor angiogenesis in numerous
cancer models, a finding that has eventually led to the
development of several drug candidates currently in clinical trials
[14,15]. Similarly, avb5 and a5b1 as well as a number of other
integrins (notably a2b1, a4b1, and a6b4) have also been shown to
play important roles in tumor angiogenesis, their pharmacological
targeting by soluble ligands or monoclonal antibodies leading to
reduced tumor microvessel density in various cancer models
[12,16]. Furthermore, at least some of the complex effects elicited
by several endogenous ECM-derived antiangiogenic fragments
(e.g., endostatin, tumstatin, endorepellin, etc) are attributed to
direct integrin engagement [17,18]. In this report, we provide
further evidence in support of the above therapeutic paradigm by
showing that the efficient disruption by a member of the
disintegrin family of multiple integrin pathways upregulated in
cancer is followed by significant tumor anti-angiogenic and pro-
apoptotic effects.
Disintegrins are among the most potent soluble ligands of
integrins representing a class of cysteine-rich polypeptides
historically isolated from the venoms of snakes belonging to the
Viperidae family [19]. These small polypeptides hold a significant
translational potential as anti-cancer agents based on their anti-
angiogenic and anti-metastatic effects demonstrated in various
experimental settings [20,21,22]. The integrin-binding activity of
disintegrins depends on the appropriate pairing of several cysteine
residues responsible for the disintegrin fold, a mobile 11-amino
acid loop protruding from the polypeptide core displaying a tri-
peptide motif, usually RGD (Arg-Gly-Asp), that is conserved in
many disintegrins [23,24]. Although these molecules naturally
evolved to efficiently bind to the activated platelet-specific integrin
aIIbb3, thus disrupting the process of platelet aggregation (the
final step in blood clotting), most purified snake venom disintegrins
are rather promiscuous in that they bind to several b1, b3o rb5
integrin members, albeit with different affinities and selectivity
[25]. Two of the most studied native disintegrins are the
homodimeric contortrostatin (CN) [26] and the monomeric
echistatin [20]. Similar to echistatin, the anti-tumor activity of
CN is based on its high affinity interaction with integrins a5b1,
avb3 and avb5 on both cancer and angiogenic endothelial cells
[27,28,29]. In a previous study [22] we showed that a liposomal
formulation of CN limited tumor growth and significantly reduced
microvascular density in a xenograft animal cancer model. We
provided evidence that CN can be safely and effectively
administered intravenously by a clinically acceptable delivery
method (i.e., liposomal delivery) and, by doing so, CN passively
accumulates at the tumor site. Furthermore, liposomal CN did not
interact with the components of blood coagulation system nor
elicit a neutralizing antibody immune response. For eventual
clinical use, however, the direct isolation of native CN from crude
venom would be laborious and prohibitively expensive since this
polypeptide only exists as a very minor fraction relative to other
venom components.
Vicrostatin (VCN) is a chimeric disintegrin generated recombi-
nantly by grafting the C-terminal tail of viperid snake venom
disintegrin echistatin to the sequence of crotalid disintegrin
contortrostatin (CN); we have previously shown [30] that this
novel sequence could be produced as an active polypeptide in
Origami B E. coli. Here, we show that VCN retains the binding
profile of CN yet it engages integrins in a unique manner. As
previously shown with native CN, VCN also appears to engage
integrins agonistically thus behaving like a soluble ECM-mimetic.
Via agonistic integrin ligation in the absence of tethering, VCN
appears to inappropriately elicit a cascade of signaling events
rapidly leading to actin stress fibers disassembly in HUVEC
(human umbilical vein endothelial cells) plated on complete
Matrigel. Moreover, in a manner reminiscent of some ECM-
derived endogenous anti-angiogenic fragments [31,32,33], VCN
interferes with the assembly of a dynamic actin cytoskeleton in
tubulogenic HUVEC sandwiched between two Matrigel layers,
negatively impacting the survival of these cells. Finally, in an effort
to address our main goal of developing an efficient and clinically
relevant delivery method for recombinant disintegrins, VCN was
packaged in a liposomal formulation (LVCN) and further
evaluated for in vivo efficacy.
Materials and Methods
Ethics Statement
All animals involved in this study were handled and euthanized
in strict accordance with good animal practice as defined by the
strict guidelines of the Institutional Animal Care and Use
Committee (IACUC) of the University of Southern California.
Controtrostatin purification
Venom of Agkistrodon contortrix contortrix was purchased from
Miami Serpentarium (Punta Gorda, FL). CN was purified in a
four-step high-performance liquid chromatography (HPLC) pro-
cedure according to an established protocol [26].
Cells and reagents
The MDA-MB-435 cells were obtained from Dr. Janet Price
(MD Anderson Cancer Center, Houston, TX) and the MDA-MB-
231 cells from Dr. Toshiyuki Yoneda (Osaka University, Osaka,
Japan). HUVEC were purchased from PromoCell (Heidelberg,
Germany) and maintained according to the manufacturer’s
protocol. The Origami B (DE3) E. coli strain and pET32a
expression vector carrying the bacterial thioredoxin A gene (trxA)
were purchased from Novagen (San Diego, CA). The oligonucle-
otide primers used for rCN and VCN cloning were synthesized by
Operon Biotechnologies, Inc. (Huntsville, AL). A southern
copperhead venom gland cDNA library, a mouse CN monoclonal
antibody, and rabbit CN polyclonal antiserum (Alpha Diagnostic
Intl., San Antonio, TX) are available in the Markland laboratory
at the University of Southern California. ‘Endothelial Cell Tube
Formation’ plates were purchased from BD Biosciences (Bedford,
MA). The tube formation inhibitor Suramin, the actin modifier
Cytochalasin D (CytoD), and the cyclo(Arg-Gly-Asp-DPhe-Val)
peptide (cRGDfV) were purchased from Calbiochem (San Diego,
CA). The fluorometric cell invasion assay kit (QCM
TM 24-Well
Cell Invasion) was from Millipore (Billerica, MA). The complete
Matrigel was from BD Biosciences. Recombinant tobacco etch
virus (TEV) protease, Calcein AM, and Rhodamine-Phalloidin
were purchased from Invitrogen (Carlsbad, CA). A column-based
fluorescein isothiocyanate (FITC)-labeling kit (EZ-Label) and an
endotoxin removal kit were purchased from Pierce (Rockford, IL).
The DeadEnd
TM Fluorometric TUNEL (terminal deoxynucleoti-
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Promega (Madison, WI). The non-selective protein kinase
inhibitor Staurosporine (STSP) was from Cayman Chemical
(Ann Arbor, MI). The murine b3 integrin 7E3 antibody was a gift
from Dr. Marian Nakata (Centocor, Horsham, PA). The murine
avb3 integrin antibody LM609 was from Millipore. The CD31
polyclonal antibody (MEC13.3) was from BD Pharmingen
(Franklin Lakes, NJ). The Ki-67 (H-300), a focal adhesion kinase
(FAK) polyclonal (A-17), and all secondary antibodies were
purchased from Santa Cruz Biotechnology (Santa Cruz, CA). A
FAK monoclonal antibody (clone 77) was from BD Biosciences. A
phosphotyrosine monoclonal antibody (P-Tyr-102) was from Cell
Signaling Technology (Danvers, MA). Purified soluble avb3 and
avb5 integrins were purchased from Millipore and soluble
recombinant a5b1 integrin from R&D Systems (Minneapolis,
MN). All other reagents were purchased from Sigma Chemical
Co. (St. Louis, MO). Avastin was a gift from Dr. Agustin Garcia
(Norris Comprehensive Cancer Center, University of Southern
California).
Construction of rCN and VCN expression vectors and
recombinant production
rCN and VCN were cloned into pET32a vector downstream of
thioredoxin A (TrxA) using a BglII/NcoI set of restriction enzymes.
The forward primers for both rCN and VCN introduced a unique
TEV protease cleavage site, which made possible the removal of
thioredoxin during purification. To build the VCN construct, the
nucleotides encoding the C-terminal tail of echistatin were added to
CN via an elongated reverse primer. The primers used for rCN
were: forward - 59gttccagatctcgagaatctttacttccaaggagacgctcctg-
caaatccgtgctgcga39, and reverse - 59gttattcgccatggcttaggcatggaagg-
gatttctgggacagccagcaga39. The primers used for VCN were:
forward - 59gttccagatctcgagaatctttacttccaaggagacgctcctgcaaatccg-
tgctgcga39, and reverse - 59gttattcgccatggcttaagtagctggacccttgtggg-
gatttctgggacagccagcagatatgcc39. Both plasmids were initially am-
plifiedinDH5aE.coli,purified and sequenced,and thentransferred
into Origami B (DE3) E. coli. Multiple cultures were established for
each construct from individual colonies of transformed BL21(DE3),
AD494 (DE3) or Origami B (DE3) in LB media containing either
carbenicillin (50 mg/mL) alone, or carbenicillin (50 mg/mL) plus
kanamycin (15 mg/mL) or carbenicillin (50 mg/mL) plus tetracy-
cline (12.5 mg/mL),pluskanamycin(15 mg/mL)andgrownat37uC
and 250 rpm in a shaker-incubator until they reached an OD600 of
0.6-1. At this point, the cells were induced in 1 mM IPTG
(isopropyl-1-b-D-thio-1-galactopyranoside) and incubated for an-
other 4–5 hours at 37uC and 250 rpm. At the end of the induction
period, the cells were pelleted at 40006g and lysed in a
microfluidizer (Microfluidics M-110L, Microfluidics, Newton,
MA). The operating conditions of the microfluidizer included
applied pressures of 14,000–18,000 psi, bacterial slurry flow rates of
300–400 ml per minute and multiple passes of the slurry through
the processor. The lysate insoluble cellular debris was removed by
centrifugation (40,0006g) and thesoluble materialcontainingeither
Trx-rCN or Trx-VCN collected. The expressed fusion proteins in
the collected soluble lysates were then proteolysed by incubation
with recombinant TEV protease overnight at room temperature
which efficiently cleaved off rCN or VCN from TrxA as monitored
by SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis). When proteolysis was complete, the proteolyzed lysates
were passed through a 0.22 mm filter, diluted 1:100 in ddH2O,
ultrafiltrated through a 50,000 MWCO cartridge (Biomax50,
Millipore) and then reconcentrated against a 5,000 MWCO
cartridge (Biomax5, Millipore) using a tangential flow ultrafiltration
device (Labscale TFF system, Millipore).
Purification of recombinant disintegrins
This was done by C18-reverse phase HPLC using the
standard elution conditions previously employed for the
purification of native CN [26]. The filtrated lysates processed
as described above were loaded onto a Vydac C18 column
(218TP54, Temecula, CA). A ten-minute rinse (at 5 ml/min) of
the column with an aqueous solution containing 0.1%TFA was
followed by a linear gradient (0–100%) elution over 150 min in
a mobile phase containing 80% acetonitrile and 0.1%TFA. rCN
starts eluting in 30% acetonitrile, while VCN elutes in 35%
acetonitrile.
Inhibition of platelet aggregation
The inhibition of ADP-induced platelet aggregation by
recombinant disintegrins was determined by measuring the light
absorption of human platelet-rich plasma (PRP) in a specialized
spectrophotometer (Chrono-log 490 optical aggregometer,
Chrono-log, Havertown, PA) as previously described [22]. The
FITC-labeled disintegrins (FITC-CN and FITC-VCN) and the
liposomal formulations of VCN were also tested for activity against
platelets.
Mass spectrometry (MS) analysis and sequencing by
tryptic digestion
The MS analysis (MALDI-TOF and ESI) was initially done by
Dr. Kym Faull (University of California at Los Angeles) and the
subsequent sequencing by Dr. Ebrahim Zandi (Keck School of
Medicine, University of Southern California). For sequencing, the
purified recombinant disintegrins were reduced, alkylated and
digested with trypsin at 37uC overnight. The resultant digestion
peptides were then used in the tandem LC/MS/MS for sequence
analysis. The LC consists of a reverse phase C-18 column through
which peptides were eluted into the mass spectrometer using the
following gradients: 5–60% acetonitrile +0.1% formic acid over
75 min and 50–90% acetonitrile +0.1% formic acid over 10 min.
Tandem MS/MS spectra was acquired with Xcalibur software on
a linear ion trap LTQ instrument. Data was analyzed using
Bioworks, the SEQUEST algorithm and Sage-N Sorcerer to
determine cross-correlation scores between acquired spectra
and NCBI protein FASTA databases or any other databases as
needed.
FAK phosphorylation studies
Serum-starved MDA-MB-435 cells were harvested by limited
trypsin/EDTA treatment [34] and maintained in suspension
before being exposed for 10–30 min to different concentrations of
either native CN or VCN. The cells were lysed and the soluble
fraction immunoprecipitated with a polyclonal FAK antibody
(clone A-17) and further assayed by Western blotting [34,35]. The
transferred proteins were probed with either a p-Tyr antibody (P-
Tyr-102, Cell Signaling Technology, Danvers, MA) or a
monoclonal FAK antibody (clone 77).
Cell surface binding studies by flow cytometry
HUVEC, MDA-MB-231 or MDA-MB-435 cells were grown to
early confluency and starved overnight in serum-free media. The
cells were harvested and resuspended in 1 ml of serum-free media
(5610
5 cells/condition) before being incubated with different
treatments or controls for 30 min at 37uC. At the end of the
incubation period, the cells were pelleted, washed in ice-cold PBS
containing 5% fetal bovine serum and either analyzed in a
FACSCalibur scanner or, depending on the assay, further
incubated at 4uC for 30 min intervals with additional treatments.
Vicrostatin - A Novel Agent
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of necrotic cells. For each reading, 10,000 cells per sample were
analyzed.
Integrin binding kinetics by fluorescence polarization
(FP)
Differing concentrations of purified soluble functional integrins
(i.e., avb3, avb5o ra5b1) were incubated with a constant amount
of FITC-labeled VCN or CN using an established protocol [36].
Upon binding to the much larger integrin, the fluorescent tag on
either disintegrin tumbles in solution at a slower rate compared to
the unbound state resulting in increased levels of polarization.
The measured FP value is a weighted average of FP values of the
bound and free fluorescent disintegrins and is therefore a direct
measure of the bound fraction. The data were analyzed as for
standard radioligand binding, and kinetics of binding determined
using Scatchard analysis and a non-linear curve fit. The data
were generated in a PTI QuantaMaster QM-4SE spectrofluo-
rometer (Photon Technology International, Birmingham, NJ)
using the PTI FeliX32 software for data acquisition and
Prism v3.02 (GraphPad Software, La Jolla, CA) for data
analysis.
Cell viability studies
HUVEC, MDA-MB-231 or MDA-MB-435 cells were plated in
serum-free media on Matrigel-coated multi-well glass chamber
slides (5610
4 cells/well) and allowed to adhere. Native CN or
VCN were added to the wells at concentrations ranging from 1–
1000 nM. Cells receiving no treatment or a known apoptosis
inducer (Staurosporine) were used as controls. The cell viability for
each condition was assessed after incubation times up to 48 hr
both colorimetrically using the Cell Titer 96 AQueous cell viability
kit (Promega, Madison, WI) according to the manufacturer’s
protocol and by TUNEL staining. For TUNEL, the cells were
stained using the DeadEnd
TM Fluorometric kit (Promega,
Madison, WI), and then counterstained with Hoechst 33342.
The TUNEL- and Hoechst-stained areas were quantitated
digitally by pixel counting on images taken from multiple slides
per condition using the ‘SimplePCI’ imaging software (Hama-
matsu Corporation, Sewickley, PA).
Inhibition of cell invasion
The ability of disintegrins to block the invasion of HUVEC,
MDA-MB-231 or MDA-MB-435 cells through a reconstituted
basement membrane was assessed using the fluorometric QCM
TM
24-Well Cell Invasion kit (Millipore, Billerica, MA). The cells were
serum-starved overnight, harvested, resuspended in serum-free
media (1610
6 cell/ml) and incubated in the presence of various
concentrations (0–1000 nM) of either native CN or VCN for
10 min at 37uC. The assay was done according to the
manufacturer’s protocol and used HT1080 conditioned media as
a chemoattractant. The invasion plates were incubated for up to
48 hr (depending on the cell line) at 37uC in the presence of 5%
CO2. At the end of the incubation period, the invaded cells were
detached, lysed and quantitated using the DNA-binding fluores-
cent dye CyQUANT. The relative fluorescence was measured in a
SPECTRAmax GeminiEM fluorescent plate reader (Molecular
Devices, Sunnyvale, CA) and the numbers averaged and plotted
for each condition.
Inhibition of HUVEC tube formation
‘Endothelial Tube Formation’ plates precoated with Matrigel
(BD Biosciences, Bedford, MA) were used according to the
manufacturer’s protocol. HUVEC were seeded in triplicate
(3610
4 cells/well) in the presence of various concentrations (0–
1000 nM) of either native CN or VCN and incubated for 16 hr at
37uC in the presence of 5%CO2. The tube formation inhibitor
Suramin was used as a positive control. At the end of incubation
period, cells were stained with Calcein AM and imaged by
confocal microscopy (LSM 510 Confocal/Titanium Sapphire
Laser). The total length of tubes for each condition was
quantitated in multiple fields using the Zeiss LSM Image Browser
(Carl Zeiss MicroImaging GmbH, Munich, Germany) and
averaged from at least three independent experiments.
Disruption of actin cytoskeleton organization
HUVEC grown in complete media were seeded in triplicate in
8-well chamber slides coated with complete Matrigel (4610
4 cells/
well). Each well received different concentrations of various
treatments {including FITC-CN, FITC-VCN, the cyclic RGD
peptide cyclo(Arg-Gly-Asp-DPhe-Val) (abbreviated cRGDfV), the
murine 7E3 or LM609 monoclonal antibodies}. The actin
modifier Cytochalasin D (CytoD) was used as a positive control.
The cells were incubated with the treatments for 3 hr at 37uCi n
the presence of 5%CO2. At the end of the incubation period, the
cells were washed, incubated with secondary treatments (depend-
ing on the condition), fixed in 4% formaldehyde, permeabilized in
0.1% Triton X-100 in PBS, and then stained with Rhodamine-
Phalloidin and counter-stained with Hoechst 33342 before being
imaged by confocal microscopy (LSM 510 Confocal/Titanium
Sapphire Laser).
In vitro Matrigel-embedded HUVEC apoptosis studies
HUVEC seeded in serum-free media in 8-well chamber slides
coated with complete Matrigel (4610
4 cells/well) were allowed to
adhere before being sandwiched with another layer of Matrigel
that was uniformly pipetted on top of the adherent cells. The
second Matrigel layer was allowed to settle before various
treatments were added and chambers incubated at 37uC in the
presence of 5%CO2 for approximately 16 hr. At the end of the
incubation period, the cells were fixed in 4% formaldehyde,
permeabilized in 0.2% Triton X-100 in PBS, TUNEL stained
using the DeadEnd
TM Fluorometric kit (Promega, Madison, WI),
and counterstained with Rhodamine-Phalloidin and Hoechst
33342. The % cell death was quantitated in random fields taken
at 6250 magnification using the formula ‘number of TUNEL
+
nuclei/total number of nuclei x100’ for each treatment group. The
TUNEL- and Hoechst-stained areas were quantitated digitally by
pixel counting on images taken in random fields from multiple
slides per condition using the ‘SimplePCI’ imaging software
(Hamamatsu Corporation, Sewickley, PA).
Liposomal encapsulation of VCN
This procedure was carried out by Molecular Express, Inc (Los
Angeles, CA) a company specializing in liposomal encapsulation of
therapeutic proteins and other drugs. Briefly, stock solutions of
phospholipids and cholesterol were prepared by dissolving each
lipid in a chloroform/methanol solvent mixture. Thin lipid films
were created by pipetting aliquots of the lipid solutions into round
bottom glass tubes followed by solvent evaporation at 65uC under
a stream of nitrogen gas with the lipids and cholesterol further
dried under vacuum for 48 hours. Dried VCN was then dissolved
in a hydration buffer (10 mM sodium phosphate and 262 mM
sucrose, pH 7.2) and added to the dried lipids. After 5 min
incubation at 50uC, liposomal VCN (LVCN) particles were
generated by either probe sonication at 10% power for 3 to
5 min in a Branson Probe Sonifier or homogenized in a
Vicrostatin - A Novel Agent
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enized material was processed between 10,000 and 18,000 psi
while maintaining an elevated temperature (45–65uC). Samples
from each batch were taken during the process and the size
distribution of LVCN was determined with an Ultrafine Particle
Analyzer (UPA150; Microtrac, North Largo, FL). After process-
ing, the unencapsulated VCN in each batch was removed by
ultrafiltration using an Amicon UF membrane of 100,000 MWCO
and the LVCN was further sterilized by filtration through a
0.2 mM PVDF filter.
In vivo efficacy studies
MDA-MB-435 cells (5610
5 per inoculum) or MDA-MB-231
cells (2610
6 per inoculum) were harvested and resuspended in
complete Matrigel and injected in the mammary fat pads of nude
mice as previously described [22]. The tumors were allowed to
grow for 2 weeks or until they became palpable before treatment
was initiated. VCN was administered either encapsulated in
different liposomal formulations (at the dose-equivalent of 100 mg
of dry VCN per injection) or non-encapsulated, as an aqueous
solution (100 mg VCN). All VCN administrations were made
intravenously (via tail vein) twice a week for the duration of each
study. Avastin was administered intravenously (via tail vein) at the
dose of 400 mg per injection (approx. 20 mg/gr.) once a week for
the duration of the MDA-MB-231 study. Tumor diameters were
measured weekly with a caliper in a blind fashion and the tumor
volumes calculated using the formula [length (mm) 6 width
(mm)
2]/2, where the width and the length were the shortest and
longest diameters, respectively [37]. The average tumor volume
for each study group was plotted as a function of time and type of
treatment during the entire course of each study.
Tumor microvessel quantitation
Acetone-fixed 5 mm-thick cryostat sections cut from MDA-MB-
231 tumors were air dried for 30 min before being blocked in 5%
BSA in PBS and incubated overnight with a rat polyclonal CD31
antibody (clone MEC13.3) at room temperature. The working
dilution for this antibody was 1/100 in 5%BSA in PBS. After
washing off the unbound CD31 antibody, a biotinylated goat anti-
rat antibody (1/150 in 5%BSA in PBS) was applied for 45 min at
room temperature followed by the Avidin Binding Complex
(Vector Laboratories, Burlingame, CA) for another 30 min and
the addition of 3-amino-9-ethylcarbazole chromogen (a peroxidase
substrate). The slides were counterstained with hematoxylin. To
quantitate the CD31-stained microvessels, the slides were
subjected to ‘random field’ analysis [38,39]. Random field images
were captured at6200 (10 images were analyzed per tumor and 4
random tumors were analyzed from each animal group). The
CD31-positive areas were quantitated for each random field as %
of total stained area by pixel counting using the ‘SimplePCI’
imaging software (Hamamatsu Corporation, Sewickley, PA). To
eliminate bias, the random field image capture and the subsequent
processing and analysis were carried out in a blind fashion.
TUNEL and Ki-67 staining of tumor sections
For tumor apoptosis, the DeadEnd
TM Fluorometric TUNEL
assay kit (Promega, Madison, WI) was used according to the
manufacturer’s protocol. Importantly, we found that the TUNEL
staining was optimal only when the cryostat sections were fixed
and permeabilized in a cold ethanol/acetic acid (2/1) bath for
5 min at 220uC. Any other fixation and/or permeabilization
technique yielded suboptimal staining results. However, this above
approach is not compatible with CD31 antibody staining, which
works best on either not-fixed or acetone-fixed tissues. After
TUNEL staining, the nuclei were counterstained with Hoechst
33342. The nuclei from apoptosis ‘hotspot’ areas were digitally
counted (object counting) using the SimplePCI imaging software
on random images (at least 10 images per tumor from multiple
tumors per group) captured at 6250. The % of cell death was
plotted using the formula ‘number of TUNEL
+ nuclei/total
number of nuclei x100’ for each treatment group. For Ki-67
staining, a primary rabbit antibody (clone H-300) and a
biotinylated anti-rabbit secondary were used. The sections were
acetone-fixed, incubated with the antibodies and prepared for
immunoperoxidase staining as described above for CD31 staining.
The Ki-67
+ nuclei were quantitated by pixel counting as % of total
stained area as described above for CD31.
Statistical analysis
Statistical significance was analyzed in Prism v.3.2 (GraphPad
Software, La Jolla, CA) by unpaired t-test followed by F-test to
compare variances. The tumor volume distribution and immuno-
histochemistry data were assessed by analysis of variance
(ANOVA) with a significant overall F-test followed by Dunnett’s
multiple comparison tests of treatment groups relative to control.
Two-tailed P,0.05 were considered significant.
Results
The recombinant production of VCN as an active soluble
protein
The expression of recombinant disintegrins was done in
Origami B (DE3), a strain uniquely designed to address the
shortcomings of disulfide-rich recombinant protein production in
wild-type E. coli. This strain is engineered to produce defective
forms of two redox enzymes that are critically involved in
controlling the major reductive pathways in this bacterium:
thioredoxin reductase (TrxB) and glutathione reductase (Gor). In
the absence of functional cytoplasmic TrxB and Gor enzymes, the
redox equilibrium in this E. coli strain is shifted towards oxidation,
a redox state that greatly promotes disulfide bond formation in
heterologous proteins expressed in this compartment [40].
The Origami B strain is better suited for recombinant protein
expression than most other commercially available E. coli strains
since, in addition to providing a favorable environment for
disulfide bond formation, by being a derivative of the BL21 strain
it is also deficient in ompT and lon proteases. Moreover, this strain
is lac permease (lacY1) deficient, a feature that enables a uniform
entry of IPTG (a lactose derivative commonly employed to trigger
the expression of recombinant proteins engineered downstream of
a lac promoter) into cells with a more homogenous level of
induction and, consequently, adjustable levels of protein
expression.
The pET32a expression vector and the T7 system are designed
for robust expression of heterologous proteins fused to the 109
amino acid bacterial thioredoxin A (TrxA) in DE3 lysogens. In
wild-type E. coli, TrxA normally functions as a major cytoplasmic
reductase under tight regulatory control. However, in the Origami
strain, the oxidative redox state perpetuated by defective TrxB and
Gor enzymes ‘tricks’ this bacterium into producing compensatory
higher amounts of TrxA reductase in an attempt to restore the
wild-type redox equilibrium which in turn drives the robust
expression of any recombinant protein genetically fused to TrxA.
Another advantage of expressing heterologous proteins fused to
TrxA is the high solubility of this bacterial protein, the result of
which is that TrxA internally chaperones the recombinant protein
fused to it thus keeping it in solution and allowing for higher levels
of foreign protein accumulation in the cytoplasm [40].
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Origami B (DE3) we generated two constructs: one based on the
exact sequence of native CN (referred to as rCN) and a chimeric
construct, previously designated as rCN+ [30], but now referred to
as vicrostatin (VCN). The VCN construct was designed by
replacing the C-terminal tail of native CN with the tail of another
native disintegrin, echistatin, a short length viperid disintegrin.
The sequence alignment of CN, rCN, VCN and echistatin (also
known as echistatin alpha) [20] are shown in Fig. 1. The rationale
for the VCN design was based on the finding that the C-termini of
snake venom disintegrins are important structural elements
essential for full disintegrin activity, and have been shown to
participate in the ligation of the receptor together with the
disintegrin loop [41]. In addition, a previous report [42] had
demonstrated that the swapping of C-terminal tails between two
native disintegrins may actually lead to the generation of novel
chimeric molecules capable of recognizing specific integrins with
altered binding affinities. Our expectation for VCN was that, by
carrying a modified C-terminus, it would display an improved
affinity compared to the native molecule for integrin a5b1, a
major player in angiogenesis. The participation of multiple regions
in disintegrins in receptor binding emphasizes the complexity of
these bigger polypeptides compared to small cyclic RGD peptides
or RGD-peptidomimetics. Moreover, these structural differences
are also expected to be reflected at the functional level, and in this
report we provide the evidence that this is the case.
By employing the recombinant system described above, two
fusion proteins (Trx-rCN and Trx-VCN) were successfully
expressed in the cytoplasm of Origami B (DE3) (see Fig. 2A for
a comparison of Trx-VCN expression levels in different expression
hosts; the data on Trx-rCN is not shown). Although the expression
of Trx-VCN was robust in Origami B (DE3), by growing these
transformants in a modified media recipe we have been able to
boost the recombinant production level of VCN by at least one
order of magnitude to a final expression yield of approximately
200 mg of active purified disintegrin per liter of bacterial culture.
A unique tobacco etch virus (TEV) protease cleavage site was
engineered upstream of both disintegrin constructs in order to
facilitate their subsequent cleavage from TrxA. TEV is a highly
selective protease that recognizes with very high specificity the
canonical Glu-Asn-Leu-Tyr-Phe-Gln-Gly amino acid sequence
[43] therefore leaving the target recombinant proteins intact. This
high specificity makes TEV an ideal molecular tool for processing
recombinant proteins expressed as fusions. Moreover, TEV is a
cysteine protease that relies on reducing equivalents (e.g.,
dithiothreitol) in order to be regenerated and act continuously.
The addition of reducing equivalents during the purification
process, however, could be detrimental to the integrity of any
expressed recombinant proteins that rely on multiple disulfide
bonds for activity. However, we found that the addition of
exogenous reducing equivalents to Origami B lysates enriched in
Trx-VCN or Trx-rCN was in fact not necessary for efficient
proteolysis, since the bacterial lysates provided enough reducing
equivalents for TEV regeneration. Therefore, the mere addition of
a few units of recombinant TEV was sufficient to optimally process
large quantities of expressed fusions (Fig. 2B). The released
recombinant disintegrins were further processed and purified by
reverse phase HPLC using a protocol originally designed for
native disintegrins (see Materials and Methods).
Initial evaluation of recombinant disintegrins for activity
The two purified recombinant molecules were initially tested for
activity against platelets. Presumably, the main function of snake
venom disintegrins in nature is to bind with very high affinity to
the activated platelet aIIbb3 integrin, thus efficiently inhibiting
[20] the last step in the blood clotting, platelet aggregation, a
process mediated by platelet integrin aIIbb3. To our surprise, the
platelet aggregation assay showed that only chimeric VCN
retained full activity against activated aIIbb3 integrin (with a
calculated IC50 of ,60 nM), whereas the rCN construct showed
no activity in the nanomolar range characteristic of snake venom
disintegrins (Fig. 2C). It appears that the latter construct, although
soluble, had failed to fold correctly in the region where the binding
site of the molecule resides (i.e., the 11-amino acid disintegrin
loop).
Mass spectrometry analysis and sequencing of VCN
Interestingly, the MS analysis (MALDI-TOF and ESI) demon-
strated that, unlike native CN, VCN is a monomer
(MW=7146.0). The sequence was subsequently confirmed by
tryptic MS sequencing. Based on these data, we speculated that
although VCN folded correctly in the C-terminal half of the
molecule, hence being a functional disintegrin, it may have
adopted a non-native cysteine pairing in the N-terminal half of the
molecule compared to CN [24] which compromised its dimeriza-
tion (see Fig. 1 for disulfide bond configuration of native CN).
Figure 1. Comparison between contortrostatin (CN), recombinant contortrostatin (rCN), vicrostatin (VCN), and echistatin
sequences. Mass spectrometry and crystallographic data have confirmed that CN is a dimer with two identical chains oriented in an antiparallel
fashion and held together by two interchain disulfide bonds. Unlike native CN, mass spectrometry showed that both rCN and VCN are monomers. In
the above sequences, the Arg-Gly-Asp tripeptide motif is depicted in bold whereas the non-native amino acids in rCN and VCN are both italicized and
underlined.
doi:10.1371/journal.pone.0010929.g001
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Native CN was previously shown to bind to integrins
agonistically [34,44], while acting as a potent soluble ECM-
mimetic [35]. Interestingly, depending of the cellular context
(adherent vs. suspended cells) CN was previously shown to alter
the phosphorylation status of FAK (i.e., one of the earliest
signaling events downstream of integrin engagement) by either
activating (in serum-starved cancer cells kept in suspension in
serum-free media and receiving no external input via integrins
other than the disintegrin treatment) or deactivating (in adherent
cells plated on various matrices) this non-receptor kinase [35]. In
the present study we wanted to understand whether VCN: 1.
retains the ability of native CN to signal via integrins agonistically
in serum-starved non-migratory suspended cells receiving no
external input other than disintegrins, and 2. has the same potency
as CN by evoking this downstream signal in a dose-dependent
manner. Our data suggest that indeed VCN also engages integrins
agonistically (Fig. 2D), with a similar potency and in a dose-
dependent manner comparable to native CN. These new data
imply that the previously described signaling effects of CN [44]
observed downstream of integrins in suspended cells were not in
fact owing to CN’s dimeric structure (i.e., signaling via receptor
crosslinking), but may have rather been the result of an intrinsic
property of the disintegrin fold, common to all disintegrins
regardless of their tertiary structure.
Cell surface binding analysis by flow cytometry
The ability of VCN to mimic the binding behavior of native CN
against different cell lines, as well as in the presence of EDTA or
specific competitors, was tested by flow cytometry (Fig. 3). Our
results show that FITC-labeled VCN has a similar binding profile
to CN against HUVEC, MDA-MB-231 and MDA-MB-435 cells.
These cells were chosen because they all express varying amounts
of the RGD-dependent integrins avb3, avb5 and a5b1, the targets
of CN, VCN and other ligands used in the study. We tested these
cells by flow cytometry for cell surface integrin expression and
found that there was a little difference in the relative amounts of
integrins avb5 and a5b1 expressed by these cells, but a significant
Figure 2. The expression, purification and initial characterization of VCN as an active disintegrin. Panel A – The production of Trx-VCN
was assessed in different E. coli strains that were transformed, grown, induced, and processed under identical conditions. The same amount (5 ml) of
cell lysates from each induced strain was loaded on a precast gel and Coomassie stained. Unlike the BL21 (DE3) strain, the lysates from both AD494
(DE3) and Origami B (DE3) strains generate a unique and consistent Trx-VCN band (shown by the arrow). By employing a modified media recipe, the
Origami B (DE3) Trx-VCN transformants achieve higher cell densities at the end of the induction time, generating up to 200 mg of soluble VCN per L
of bacterial culture after purification. Panel B – Coomassie stained gel showing the migration of Trx-VCN before and after TEV proteolysis (lanes 2
and 3, respectively) versus C18 reverse phase-HPLC purified VCN (lane 4). Panel C – VCN and native CN exhibit an almost identical dose-dependent
inhibitory effect against ADP-induced platelet aggregation when incubated with human platelet-rich plasma (with a calculated IC50 of ,60 nM). In
contrast, the rCN construct, which is also expressed as a soluble polypeptide in Origami B (DE3), shows no inhibitory activity. Panel D – The agonistic
activity of VCN (FAK activation) was assessed in serum-starved non-migratory MDA-MB-435 cells kept in suspension and exposed to increasing
concentrations of disintegrins for 30 min. Similar to dimeric CN, VCN is also shown to engage integrins agonistically (outside-in signaling).
doi:10.1371/journal.pone.0010929.g002
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MB-435 expressing much higher amounts of this integrin
compared to the other two cell lines, and MDA-MB-231
expressing the least amount. We also found that cell surface-
bound VCN is recognized by rabbit polyclonal CN antiserum and
bound VCN has the ability to block the binding of FITC-labeled
CN, while a specific competitor, the 7E3 antibody raised against
b3 integrin, is shown to block the binding of both FITC-labeled
CN and VCN. Interestingly, regarding the latter observation, the
converse appears to be also true for bound CN alone, Trx-VCN
alone, or VCN plus polyclonal CN antiserum, since all these
prevented the binding of 7E3 to the cell surface. However, VCN
alone did not (data not shown), which led us to the conclusion that
7E3’s binding site on b3 integrin [45] must map very closely to the
ligand-recognition region for both disintegrins. As reported by
Artoni et al. [45] 7E3’s binding site was mapped between the
C177-C184 loop and W129 residue in human b3 integrin subunit,
in a region that is spatially close to the b3 subunit MIDAS (metal-
ion dependent binding site), where the Asp residue of the RGD
motif is also known to bind. Similar flow cytometry results were
observed when the cyclic RGD peptide, cyclo(Arg-Gly-Asp-DPhe-
Val) was used as a competitor instead of 7E3. When these cells
were pre-incubated with micromolar concentrations of this cyclic
RGD peptide before being exposed to fluorescently-labeled
disintegrins, the cyclic RGD treatment also prevented the binding
of both disintegrins. Unlike 7E3, the flow cytometry analysis
showed that the avb3-specific monoclonal antibody LM609 [46]
does not compete for the same binding region with either CN or
VCN (data not shown). Finally, since the engagement of integrins
by disintegrins was previously shown to be a metal-ion depended
process [41], we asked whether a metal chelator such as EDTA
will affect the binding of both CN and VCN. As expected, both
CN and VCN did not bind to cells that were washed in 3 mM
EDTA before being exposed to either disintegrin. However, once
CN or VCN bound to the cell surface, the subsequent addition of
EDTA does not appear to displace either disintegrin from their
receptors (Fig. 3).
Integrin binding kinetics by fluorescence polarization
To further determine the specific binding affinities of both
native CN and VCN to purified (avb3 and avb5) or recombinant
(a5b1) functional integrins, we measured these interactions in
Figure 3. Binding analysis of FITC-labeled disintegrins by flow cytometry. Panel A – Both CN and VCN are detected at cell surface when
probed with CN polyclonal antiserum. MDA-MB-435 cells were incubated with either VCN (red) or CN (green) followed by CN rabbit polyclonal
antiserum and an anti-rabbit FITC-labeled secondary antibody. The controls included cells incubated with either anti-rabbit FITC-labeled secondary
only (grey) or CN antiserum followed by the FITC-labeled secondary (blue). Panels B, C – FITC-CN (panel B) or FITC-VCN (panel C) fail to bind to cells
prewashed in EDTA media, but once bound in regular media the subsequent addition of EDTA does not displace them from integrins. MDA-MB-435
cells were either incubated with FITC-labeled disintegrins only (grey) or with labeled disintegrins and then washed and resuspended in 3 mM EDTA
media (green) or preincubated in 3 mM EDTA and then washed and exposed to labeled disintegrins (red) or just probed with an FITC-labeled
irrelevant antibody control (blue). Panels D, E and F – Labeled disintegrins bind in a similar manner to cells with different integrin profiles. MDA-MB-
435, MDA-MB-231 or HUVEC were either incubated with FITC-CN (green) or FITC-VCN (red) or probed with an FITC-labeled irrelevant antibody control
(blue). Panels G, H, I and J – FITC-labeled disintegrins fail to bind to cells pretreated with either unlabeled disintegrins or an antibody competitor.
MDA-MB-435 or MDA-MB-231 cells (panels G and H) were either incubated with FITC-CN only (grey) or an FITC-labeled irrelevant antibody control
only (blue) or preincubated with unlabeled VCN (green) or 7E3 (red) and then probed with FITC-CN. Similarly, MDA-MB-435 or MDA-MB-231 cells
(panels I and J) were either incubated with FITC-VCN only (grey) or an FITC-labeled irrelevant antibody control only (blue) or preincubated with
unlabeled CN (green) or 7E3 (red) and then probed with FITC-VCN. The data are representative of four independent experiments.
doi:10.1371/journal.pone.0010929.g003
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the dissociation constants for both native CN and VCN (Table 1)
were deduced. These data showed that both disintegrins exhibit
nearly identical affinities for avb3 and a similar affinity for avb5.
The prediction that the sequence modification of VCN would alter
its affinity for a5b1 compared to the native molecule was
confirmed by this assay. The results demonstrated that there is
at least an order of magnitude difference in these molecules’ Kd
values to a5b1 with VCN showing a higher binding affinity for this
receptor (the average Kd values for integrin a5b1 were 15.2 nM
for VCN, and 191.3 nM for native CN).
Cell viability studies with adherent cells
To understand how VCN affects cell viability, we tested a range
of CN and VCN concentrations (1–1000 nM) on HUVEC, MDA-
MB-231 and MDA-MB-435 cells seeded on top of Matrigel (see
Materials and methods) and compared the results to either
untreated cells or cells exposed to Staurosporine, a known
apoptosis inducer. Neither disintegrin showed any significant
impact on cell viability regardless of the length of the incubation
time (up to 48 hr) these cells were exposed to disintegrins. The cell
viability was monitored using a MTS-based colorimetric assay and
further confirmed by TUNEL staining (Fig. 4). In this later assay,
at the end of the incubation period, the cells from all conditions
were fixed in 4% formaldehyde, permeabilized in 0.2% Triton X-
100, FITC-TUNEL stained, and then counterstained with
Hoechst 33342. The amount of cell death was plotted for each
condition by counting the apoptosis events in random fields from
multiple independent experiments using the formula ‘number of
apoptotic nuclei/total number of nuclei x 100’. Irrespective of the
cells tested, neither CN nor VCN caused cell death under these
conditions.
Inhibition of cell invasion through a reconstituted cell
membrane
The anti-invasive properties of VCN were tested in vitro using a
modified Boyden chamber assay where serum-starved HUVEC,
MDA-MB-231 or MDA-MB-435 cells were preincubated with
various concentrations of disintegrins (1–1000 nM) for 10 min
before being seeded into Matrigel-coated (ECMatrix
TM, Millipore)
porous inserts (pore size, 8 mm) and allowed to invade against a
chemoattractant gradient (HT1080 human fibrosarcoma condi-
tioned media) for up to 48 hr (depending on the cell line). At the
end of the incubation time, the cells that invaded into the lower
chamber were detached, lysed, stained with CyQuant and
quantitated in a fluorescent plate reader. The fungal metabolite
Cytochalasin D, a potent inhibitor of actin polymerization, was
used as a positive control at a concentration of 200 nM. Similar to
native CN, VCN is shown to significantly inhibit HUVEC, MDA-
MB-231 or MDA-MB-435 cell invasion in a dose-dependent
manner (Fig. 5).
Inhibition of HUVEC tube formation
The ability of VCN to inhibit HUVEC tubulogenesis was tested
in vitro in an assay where HUVEC were plated on ‘Endothelial Cell
Tube Formation’ plates (BD Biosciences) in the presence of
various concentrations of either CN or VCN (1–1000 nM) and
allowed to form tubes after incubation for 12–16 hr at 37uC in the
presence of 5%CO2. In this experimental setting, Suramin, a
known tube formation inhibitor, was used as a positive control at
two different concentrations (50 and 100 mM). At the end of
incubation period, the cells were stained with Calcein AM and
imaged by confocal microscopy. As previously reported with
native CN [47], VCN was also shown to potently inhibit HUVEC
tube formation in a dose-dependent manner (Fig. 6i). In this
assay, the tubes in each field were measured by three individuals in
a blinded experiment and the total tube length averaged and
plotted for each data set (Fig. 6ii).
Disruption of HUVEC actin cytoskeleton organization
To assess the effect of VCN on cell morphology and actin
cytoskeleton organization, HUVEC were allowed to adhere to
complete Matrigel before being exposed to various treatments.
Our results show that unlike other integrin ligands, including a
small cyclic RGD peptide, and two integrin-binding antibodies
(7E3 and LM609), VCN potently collapses the actin cytoskeleton
of HUVEC in the low nanomolar range (Fig. 7). However, unlike
VCN which exerts its maximal effects on the actin cytoskeleton of
HUVEC in the low nanomolar range (10–100 nM), the cyclic
RGD peptide used in the study appears to have some minor effects
on the actin cytoskeleton of these cells (i.e., partial disassembly of
stress fibers) only at a much higher concentration (10 mM).
Moreover, the effect observed with VCN can be only partially
prevented if the cells are preincubated with either the 7E3
antibody or the cyclic RGD peptide cRGDfV before being
exposed to the recombinant disintegrin (data not shown). It is
noteworthy that VCN does not detach HUVEC plated on
Matrigel. Complete Matrigel is a tumorigenic matrix that was
shown to be very similar in ECM composition to basement
membranes (it is rich in collagen IV and laminins) and a number
of collagen- and laminin-binding integrins (e.g., a1b1, a2b1, a3b1,
a6b1, and a6b4) are employed by various cells to attach to
Matrigel in a RGD-independent manner. On the other hand,
VCN is an RGD-displaying polypeptide that was shown to bind to
at least 4 RGD-recognizing integrins (i.e., aIIbb3, avb3, avb5,
and a5b1) but may, although not investigated yet, also bind to
other RGD-dependent integrins. For instance, there are 8 human
integrin members that have been described to recognize the RGD
motif: all av integrins (avb1, avb3, avb5, avb6, and avb8),
aIIbb3, a5b1, and a8b1. Because HUVEC do express collagen-
and laminin-binding integrins that enable these cells to attach to
Matrigel in a RGD-independent manner, it is not surprising that
VCN does not detach HUVEC from Matrigel when these cells are
exposed to the agent. However, the massive actin cytoskeleton
reorganization induced by VCN in Matrigel-plated HUVEC
raises the possibility that some of these effects might be relayed
agonistically via one or a combination of integrins that VCN is
know to bind to (i.e., transdominant integrin inhibition via either
avb3, avb5, a5b1, or a combination of these receptors), integrins
that are also expressed by these cells. Nonetheless, the observed
signaling events induced by VCN in Matrigel-plated HUVEC
Table 1. Disintegrin-integrin biding kinetics by fluorescence
polarization.
Disintegrin Integrin Kd (+/2SD)
avb3 a5b1 avb5
CN 6.6 nM (0.8) 191.3 nM (65.2) 19.5 nM (5.7)
VCN 7.4 nM (0.4) 15.2 nM (4.2) 41.2 nM (12.3)
The binding kinetics were calculated from the fluorescence anisotropy data
generated by the steady state binding of FITC-labeled disintegrins to either
purified (avb3a n davb5) or recombinant (a5b1) functional human integrins.
The dissociation constants for interactions of either CN or VCN with soluble
integrins were determined by Scatchard analysis using a non-linear curve fit.
doi:10.1371/journal.pone.0010929.t001
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better understand the complex integrin cross-talk associated with
HUVEC adhesion, migration and invasion in tumorigenic
matrices.
Induction of apoptosis in tubulogenic HUVEC embedded
in Matrigel
As stated above, VCN does not affect HUVEC viability if
adherent cells plated on top of Matrigel are exposed to this agent,
but it has significant anti-proliferative and anti-migratory effects
(inhibition of tube formation) on these cells. Interestingly, when
HUVEC are sandwiched between two layers of complete
Matrigel, a significant apoptotic effect is also observed in the
presence of VCN, but not with other integrin ligands (Fig. 8i).
Surprisingly, a similar effect was also seen with Avastin in this
setting, though less pronounced than with VCN. It is noteworthy
that the cells sandwiched between two Matrigel layers were
observed to migrate and form tubes much faster than HUVEC
plated on top of Matrigel. The faster migrating cells sandwiched in
Matrigel may rely more on the integrity of their focal adhesions
coupled with a more dynamic actin cytoskeleton not only for
migration, but also for survival. Thus, the profound effect induced
by VCN on the actin cytoskeleton of these cells may explain the
discrepancy seen in cell survival between the two experimental
settings. It is also important to note that, unlike the two integrin
binding antibodies, the cRGDfV peptide did alter the morphology
Figure 4. VCN does not affect the viability of cells plated on
top of Matrigel. HUVEC, MDA-MB-231 or MDA-MB-435 cells were
seeded in serum-free media in multiwell chamber slides on complete
Matrigel and allowed to adhere for 1 hr. Once adherent, the cells were
incubated for up to 48 hr with either CN or VCN up to a maximum
concentration of 1 mM. Untreated cells or cells exposed to the apoptosis
inducer Staurosporine (STSP) at a concentration of 1 mM were used as
controls. The cells were fixed, TUNEL-stained and counterstained with
Hoechst 33342. The amount of cell death was plotted for each
condition by digitally counting the apoptosis events in random fields
from images taken from multiple experiments for each condition.
doi:10.1371/journal.pone.0010929.g004
Figure 5. VCN inhibits cell invasion through a reconstituted basement membrane in a dose-dependent manner. The anti-invasive
properties of VCN were tested in a modified Boyden chamber assay where serum-starved HUVEC, MDA-MB-231 or MDA-MB-435 cells were
preincubated with various concentrations of disintegrins (1–1000 nM) for 10 min before being seeded into Matrigel-coated (ECMatrix
TM, Millipore)
porous inserts (pore size, 8 mm) and allowed to invade against a chemoattractant gradient (HT1080 human fibrosarcoma conditioned media) for up
to 48 hr. The fungal metabolite Cytochalasin D, a potent inhibitor of actin polymerization, was used as a positive control at a concentration of
200 nM. The above data were averaged from three independent experiments for each cell line tested.
doi:10.1371/journal.pone.0010929.g005
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although to a lesser extend than VCN and with no impact on cell
viability. The amount of cell death was quantitated digitally (the
‘SimplePCI’ software) for each condition by counting the apoptosis
events in multiple random fields from images taken from multiple
experiments using the formula ‘number of apoptotic nuclei/total
number of nuclei x 100’. The quantitation data (Fig. 8ii) was
generated from four independent experiments.
Figure 6. VCN inhibits HUVEC tube formation (tubulogenesis). (i) HUVEC were plated on ‘Endothelial Cell Tube Formation’ plates (BD
Biosciences) in the presence of various concentrations of either CN or VCN (1–1000 nM) and allowed to form tubes after incubation for 12–16 hr at
37uC in the presence of 5%CO2. Suramin, a known tube formation inhibitor, was used as a positive control at two different concentrations (50 and
100 mM). At the end of the incubation period, cells were stained with Calcein AM and imaged by confocal microscopy (magnification, 625).
Representative figures from three independent experiments are shown above (scale bar, 200 mm). (ii) The degree of tubulogenesis was assessed by
capturing multiple photomicrographs for all conditions on which the total length of the tubes was measured and computed in multiple fields using
the Zeiss LSM Image Browser (Carl Zeiss MicroImaging GmbH) and then averaged to form each data point. The data presented above was assembled
from three independent experiments.
doi:10.1371/journal.pone.0010929.g006
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Some theoretical advantages associated with liposomal encap-
sulation include: (i) enhanced drug delivery by increased tumor
entrapment (passive targeting), (ii) prolonged drug half-life and
thus reduced dosing frequency, and (iii) fewer drug-related
toxicities. Our previous study showed that liposomal CN has: no
immunogenicity, extended circulatory half-life, and undetectable
non-target effects [22]. In the present study, batches of LVCN
were prepared by sonication (LVCN-S) or homogenization
(LVCN-H) using different processing conditions. Due to some
favorable structural attributes characteristic of the disintegrin class
of polypeptides (i.e., hydrophilicity, excellent stability in solution,
at low pHs, in organic solvents, and to a range of temperatures),
we found that CN and VCN can be readily encapsulated in
liposomes with high efficiencies while retaining full biological
activity. The encapsulation efficiency for these batches was 70% or
greater (the average size of homogenized LVCN was 83 nm).
In vivo efficacy studies with LVCN
The initial efficacy evaluation of LVCN formulations was done
in the MDA-MB-435 animal model [48]. Although the breast
origin of this human cell line is controversial and currently under
scrutiny [49,50], these cancer cells are a high integrin avb3
expressor and thus constitute a good model for screening
pharmacological inhibitors directed at this receptor. In the
MDA-MB-435 model, nude mice were inoculated orthotopically
(mammary fat pads; 5610
5 MDA-MB-435 cells in complete
Matrigel per mouse) and tumors allowed to grow until they
became palpable before the treatments were initiated. The animals
(n=5) were treated twice a week with liposomal formulations of
VCN that were prepared either by sonication (LVCN-S) or
homogenization (LVCN-H). Animals receiving saline or unencap-
sulated VCN (at the dose of 100 mg per injection administered
twice weekly intravenously via tail vein) were used as controls. In
this animal model both LVCN formulations showed good tumor
Figure 7. VCN induces massive actin cytoskeleton reorganization in HUVEC seeded on Matrigel. HUVEC were seeded in serum-free
media in multiwell chamber slides on complete Matrigel, allowed to adhere, and then treated for 3 hr with various concentrations of cRGDfV peptide
(1 and 10 mM) or FITC-VCN (10 and 100 nM) or the monoclonal antibodies 7E3 (100 nM) or LM609 (100 nM). When cells were incubated with integrin-
binding antibodies (7E3 or LM609), a FITC-conjugated secondary antibody was used to track these treatments. The actin modifier Cytochalasin D was
used as a positive control (50 nM). At the end of the incubation period, the cells from all conditions were fixed in 4% formaldehyde, permeabilized in
0.1% Triton X-100, stained with Rhodamine-Phalloidin and Hoechst 33342, and imaged by confocal microscopy. The cells exposed to FITC-labeled
treatments (VCN or integrin-binding antibodies) are triple stained. The images shown above are Rhodamine-Hoechst only (panels A–B and E–F), FITC-
Hoechst (panels C2-D2 and G2-H2) or overlayed three fluorophores (panels C1-D1 and G1-H1). Representative confocal images from multiple
experiments taken at the same magnification (6630) are shown above (scale bar, 20 mm).
doi:10.1371/journal.pone.0010929.g007
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PLoS ONE | www.plosone.org 12 June 2010 | Volume 5 | Issue 6 | e10929Figure 8. VCN induces apoptosis in tubulogenic HUVEC seeded between two Matrigel layers. HUVEC were seeded in serum-free media in
multiwell chamber slides on complete Matrigel, allowed to adhere for 1 hr after which another layer of complete Matrigel was uniformly pipetted on
top of the adherent cells. After another hour of incubation, different treatments were added to the media: either VCN (100 and 1000 nM), the cRGDfV
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and the overall effect on tumor growth inhibition quantitated
(Fig. 9). LVCN was further tested in the MDA-MB-231 breast
carcinoma model with similar results (Fig. 10). In the latter model,
LVCN was compared to Avastin by looking at several parameters:
tumor growth inhibition efficacy, animal survival and reduction in
microvessel density. Avastin (bevacizumab), is a monoclonal
antibody that interferes with neo-vessel formation in tumors by
trapping an essential growth factor for angiogenesis, VEGF-A
(vascular endothelial growth factor A), currently representing the
gold standard for antiagiogenesis therapy, being approved by the
FDA for the treatment of several types of solid cancers [51]. In the
MDA-MB-231 model nude mice inoculated orthotopically
(mammary fat pads; 2.5610
6 MDA-MB-231 cells in complete
Matrigel per mouse) were allowed to grow palpable tumors before
treatment was initiated. The groups of animals (n=10) were
treated intravenously with either LVCN-H or LVCN-S (the dose-
equivalent of 100 mg of VCN per injection) each administered
twice a week, or Avastin (400 mg per injection; approx. 20 mg/gr)
administered once a week. The control group received empty
liposomes only. Another control group received unencapsulated
VCN (at the dose of 100 mg per injection administered twice
weekly intravenously via tail vein). When compared to the empty
liposomes group, a significant delay in tumor growth was observed
in all treatment groups. More importantly, in this model LVCN
was found to significantly increase the survival of the animals
similar to Avastin (all control animals in this model died by the end
of week 7). As mentioned, both animal models included a control
group that received unencapsulated VCN. Interestingly, although
the direct injection of unencapsulated VCN at the above dose
appeared to be well tolerated by the animals for the duration of the
study, in neither model was there a significant therapeutic
response as compared to the LVCN group (data not shown).
In vivo evaluation of LVCN for anti-angiogenic activity
Tumor specimens from the MDA-MB-231 model were
prepared for CD31 staining and microvessels quantitated as
described in the ‘Materials and methods’ section. Tumor cryostat
sections from all groups were fixed in acetone, stained with a
polyclonal CD31 antibody (clone MEC13.3) and counterstained
with hematoxylin. For microvessel quantitation, random CD31-
positive areas in multiple fields on sections from multiple tumors
were counted using a computer-assisted method (the ‘SimplePCI’
imaging software) and plotted as % of total stained area. Our data
shows a dramatic reduction (.80%) in microvessel density in the
LVCN group compared to the empty liposome control, and
similar to the Avastin-treated group (Fig 10).
In vivo evaluation of LVCN for pro-apoptotic and
anti-proliferative activities
The effect of LVCN on tumor cell death or proliferation was
also evaluated in the MDA-MB-231 model. Unlike the efficacy
study, in this study tumors were allowed to become more
established (4 weeks from inoculation) before a short course of
treatment (6 doses) with either LVCN or Avastin was initiated.
Our results show that there was a large difference in the amount of
cell death (TUNEL staining) between either LVCN- or Avastin-
treated groups and the control. As mentioned above, the difference
in tumor proliferation was assessed by Ki-67 staining, a commonly
employed proliferation marker with prognostic value in various
human malignancies including breast cancer [52,53]. Although
there were statistically significant differences in the amount of Ki-
67 staining between the groups, the LVCN group showing the
least amount of staining, these differences were much smaller than
the ones observed for cell death (Fig. 11). We chose to quantitate
the effects of various treatments on tumor apoptosis and
proliferation in more established tumors that received only a
short course of therapy rather than in tumors harvested at the end
of the efficacy study (after 7 weeks of treatment). The reason for
this decision was because in the study shown in Fig. 10, despite
the significant differences found in tumor size and animal survival
between the treated groups and control, we did not see similar
differences in tumor apoptosis nor in proliferation possibly due to
the ability of both LVCN and Avastin to induce tumor
stabilization/dormancy after repeated administration over a
longer period of time (data not shown).
Discussion
Tumor angiogenesis involves a still poorly understood cross-
talk between transformed epithelial cells and quiescent endo-
thelial cells originating from preexisting vessels. In this process,
peptide (1 and 10 mM), Avastin (100 nM), the b3 integrin 7E3 antibody (100 nM) or the avb3 integrin antibody LM609 (100 nM). Staurosporine (STSP),
a known HUVEC apoptosis inducer and actin modifier, was used as a positive control at two different concentrations (100 and 1000 nM). The cells
were then incubated for 16 hr at 37uC in the presence of 5%CO2. At the end of the incubation period, the cells from all conditions were fixed in 4%
formaldehyde, permeabilized in 0.2% Triton X-100, FITC-TUNEL stained, and counterstained with Rhodamine-Phalloidin and Hoechst 33342. (i)
Representative confocal images from multiple experiments taken at 6250 magnification are shown above (scale bar, 40 mm; panels A1-J1 –all
fluorophores overlayed, panels A2-J2 - FITC-Hoechst). (ii) The amount of cell death was plotted for each condition by counting the apoptosis events
from multiple random fields using the formula ‘number of apoptotic nuclei/total number of nuclei x 100’. The data shown above was generated from
four independent experiments.
doi:10.1371/journal.pone.0010929.g008
Figure 9. The initial evaluation of liposomal formulations of
VCN in the MDA-MB-435 xenograft model. Nude mice were
inoculated orthotopically (mammary fat pads; 5610
5 MDA-MB-435 cells
in complete Matrigel per mouse) and tumors allowed to grow until they
became palpable before the treatments were initiated (indicated by the
arrow). The animals (n=5) were treated twice a week with liposomal
formulations of VCN that were prepared either by sonication (LVCN-S)
or homogenization (LVCN-H). The latter method of encapsulation is
suitable for scale-up production and was done in a microfluidizer. All
LVCN-treated animals received the dose-equivalent of 100 mg of VCN
per injection and were compared to a control group that received saline
only. All treatments were administered intravenously twice a week via
tail vein. The statistical analysis was done using ANOVA with Dunnett’s
post-hoc multiple comparison tests (* signifies a P,0.001). The
liposomal formulations tested showed comparable efficacies. This
animal model was repeated three times.
doi:10.1371/journal.pone.0010929.g009
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conjunction with multiple paracrine and autocrine loops are
required to be precisely coordinated spatiotemporally for the
successful execution of a specialized migratory program
activated in quiescent endothelial cells [54]. As key regulators
of cell migration, integrins function as centripetal signaling
platforms or functional hubs [55] that bi-directionally integrate
signaling circuitries downstream of different classes of cell
surface receptors (e.g., the semaphorin/plexin/neuropilin, the
growth factor/receptor tyrosi n ek i n a s ea n dt h ec e l ls u r f a c e
protease systems) with the cellular locomotor apparatus [56]. In
angiogenesis, integrins are known to regulate many cell
decisions associated with this program by integrating the
cellular viability pathways with various processes ranging from
ECM deposition and degradation, directional endothelial cell
migration and assembly into primitive cords, to lumen
formation and vessel maturation [57,58]. The precise spatial
distribution of integrin-binding motifs encoded in normal and
oncogenic variants of ECM polymers [59] is likely to represent
the most important organizing principle of the dynamics of focal
adhesion complexes assembleda c r o s sp l a s m am e m b r a n e s ,
which coordinate via integrins the motility in both angiogenic
endothelial and metastatic cancer cells. The efficient disruption
of various integrin-mediated interactions formed between
tumorigenic ECMs and angiogenic EC in tumoral microenvi-
ronments seems to be critical from the therapeutic standpoint
since, as recently reported [60], one important downside of
pharmacologic VEGF/PDGF blockade is the persistence of
basement membranes from involuted tumor vessels after both
EC and pericytes undergo regression. This neo-vascular ECM
that is left behind in the course of anti-angiogenesis therapy is
suspected to provide a critical scaffold leading to a rapid
repopulation of these ECM ‘tracks’ by new EC once the anti-
VEGF/PDGF treatment is discontinued, in a process in which
integrins probably play a major role.
The critical involvement of integrins in both angiogenesis
[55,61] and tumor metastasis [6] provides the rationale for
developing therapeutic antagonists aimed at disrupting these
molecularly intertwined processes [14]. Nonetheless, the develop-
ment of efficacious integrin-targeted anti-cancer agents is compli-
cated by the fact that multiple members of the integrin family
appear to be differentially involved in distinct phases of tumor
angiogenesis [55] and possibly metastasis, and a clear understand-
ing of what combination of integrins is optimally required to be
simultaneously targeted in order to efficiently disrupt these
processes is still lacking. For instance, most efforts in the past
were channeled at developing pharmacological agents directed at
the RGD-binding alphav integrin members, a subclass of integrins
thought to play pivotal roles in the regulation of pathological
angiogenesis. These efforts led to the development of small RGD-
Figure 10. The efficacy and anti-angiogenic activity of LVCN in the breast MDA-MB-231 xenograft model. (i) Nude mice inoculated
orthotopically (mammary fat pads; 2.5610
6 MDA-MB-231 cells in complete Matrigel per mouse) were allowed to grow palpable tumors before
treatment was commenced (indicated by the arrow). The groups of animals (n=10) were treated intravenously with either LVCN-H or LVCN-S (the
dose-equivalent of 100 mg of VCN per injection) each administered twice a week, or Avastin (400 mg per injection; approx. 20 mg/gr) administered
once a week. The control group received empty liposomes only. When compared to the control group, a significant delay in tumor growth was
observed in all treated groups. (ii) The animal data shows increased survival in all treated groups compared to the control group (all control animals
died by the end of week 7) (iii) Tumor cryostat sections from all groups were fixed in acetone, stained with a polyclonal CD31 antibody (clone
MEC13.3) and counterstained with hematoxylin. Representative CD31 photomicrographs are shown above (scale bar, 100 mm). (iv) For microvessel
quantitation, random CD31-positive areas from multiple fields were counted using a computer-assisted method (the ‘SimplePCI’ imaging software)
and plotted as % of total stained area. Similar to Avastin, our data indicates that VCN exhibits potent anti-angiogenic activity in this animal model.
ANOVA was used for statistical analysis followed by Dunnett’s multiple comparison tests (* signifies a P,0.001).
doi:10.1371/journal.pone.0010929.g010
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antibodies [15,62]. The striking discrepancy that had been noticed
to exist, however, between the genetic and pharmacologic models
of alphav integrin ablation [10] prompted a reevaluation of these
receptors as regulators of angiogenesis [63] and attempted to
explain some of the disappointing results generated with alphav
integrin targeting agents in clinical trials. The fact that mice
deficient in either b3o rb5 or both b3 and b5 integrins not only
develop normally, but paradoxically show an enhanced tumor
angiogenic response [10] when challenged postpartum supports
the idea that these two integrins might act in a more complex way
than originally thought as regulators of pathological angiogenesis,
and may be endowed with an unexpected tumor suppression
function. Moreover, a tumor suppression function for alphav
integrins appears to also exist in epithelial cells since the genetic
ablation of alphav integrin gene in epithelial cells of murine skin
leads to development of squamous cell carcinomas [64]. In order
to reconcile these contradictory observations regarding the
contextual role of alphav integrins alternative hypotheses must
be explored. It is conceivable, for instance, that while the
overexpression of alphav integrins in angiogenic endothelial cells
may be an important requirement in regulating the migration of
these cells on solid ECM support (tethered migration) which leads
to their assembly into neovessels (a net pro-angiogenic effect), in
the presence of monovalent soluble ECM fragments a cascade of
inappropriate signals might be initiated and relayed through the
same alphav receptors (in the absence of tethering) which
ultimately may lead to cessation of cell migration and a dramatic
reorganization of actin cytoskeleton in cells exposed to such
ligands (a net anti-angiogenic effect). Although in the course of
pathological angiogenesis these two mechanisms might coexist, in
the tumor microenvironment the abundance of pro-angiogenic
circuitries, driven by a continuous deposition of new ECM
polymers, appears to render the anti-angiogenic signals ineffectual
thus favoring a perpetual state of angiogenesis. Even though other
members in the integrin family have also been linked to different
forms of angiogenesis (in development vs. adult life, physiological
vs. pathological), we speculate that the alphav members may play
critical roles in promoting and, possibly more importantly,
terminating the cell migration events associated with angiogenesis
Figure 11. LVCN treatment shows enhanced tumor apoptosis in the breast MDA-MB-231 xenograft model. For this experiment, MDA-
MB-231 xenografts were allowed to grow to a significantly larger volume (4 weeks after inoculation) before treatments were initiated. The animals
received either liposomal VCN (at the dose-equivalent of 100 mg of VCN per injection) or Avastin (400 mg per injection) administered intravenously
every other day and compared to a control group that received saline only. All animals were sacrificed after receiving 6 consecutive doses of each
treatment. (i) To assess the impact of VCN on cell death, tumor cryostat sections from each group were stained with FITC-TUNEL, and counterstained
with Hoechst 33342. Representative confocal images from multiple experiments taken at 6250 magnification are shown above (scale bar, 100 mm;
panels A1-C1 - TUNEL-Hoechst, panels A2-C2 - TUNEL only). (ii) The amount of cell death was quantitated as ‘number of TUNEL
+ nuclei/total number of
nuclei x 100’ by counting all nuclei in ‘hotspot’ areas from multiple fields using a computer-assisted approach (the ‘SimplePCI’ imaging software). The
liposomal VCN group shows a significantly increased amount of cell death compared to either Avastin or control. (iii) The impact of VCN treatment
on tumor proliferation was assessed by Ki-67 immunoperoxidase staining. Representative Ki-67 images are shown above (scale bar, 200 mm). (iv) Cell
proliferation was quantitated using the same approach as for TUNEL staining. The differences in cell proliferation between the treatment groups were
much smaller than those observed for cell death. The data was analyzed with ANOVA followed by post-hoc tests (* signifies a P,0.01).
doi:10.1371/journal.pone.0010929.g011
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between genetic and pharmacological models of alphav integrin
ablation, providing a rationale for why animals devoid of b3 and
b5 integrins display increased pathological angiogenesis postpar-
tum. A number of endogenous ECM-derived fragments with anti-
angiogenic activity have been characterized to date [17,65], and
some of these promising molecules were found to bind to either
one or multiple integrin receptors (i.e., endostatin, tumstatin,
arresten, canstatin, PEX, endorepellin etc) [66]. It is noteworthy
that the integrin ligation by some of these endogenous fragments
(i.e., endostatin, endorepellin) was shown to lead to the collapse of
actin cytoskeleton and focal adhesion disassembly in endothelial
cells in vitro [32,33]. Interestingly, these cell motility deactivation
effects observed in angiogenic endothelial cells with ECM
fragments are reminiscent of those triggered by members [67,68]
belonging to an unrelated class of signaling molecules (i.e., the
semaphorins) which suggest that a high degree of integration may
exist between the semaphorin-plexin-neuropilin and integrin
systems in controlling the actin cytoskeleton dynamics during
angiogenesis [57]. It could be argued that, if integrins physically
connect the actin cytoskeleton with a plethora of complex
molecules bound across plasma membrane, thus enabling the
dynamic actin cytoskeleton in migratory cells to sense their
extracellular microenvironment, then a pharmacological agent
designed to efficiently disrupt integrins is also expected to induce a
massive reorganization or collapse of actin cytoskeleton in these
cells. Since some of the endogenous ECM-derived anti-angiogenic
fragments have already been characterized as potent tumor
suppressors in various animal models, the biggest stumbling block
to their successful clinical translation remained the ability to
produce them recombinantly in large scale. However, this proved
to be more complicated than originally thought due to the fact that
these ECM fragments are naturally derived through proteolytic
cleavage from higher molecular weight matrix polymers which
makes them dependent on their parental supermolecules for
correct folding (i.e., intramolecular chaperoning). Because of this,
these otherwise promising molecules proved to be refractory to
correct folding when expressed in various recombinant systems,
which led to altered or diminished biological activity for the
recombinant versions when compared to the native ECM
fragments, an issue that may have accounted for the disappointing
performance seen with recombinant endostatin in clinical trials
[66].
Interestingly, several classes of metalloproteases found in snake
venoms also contain domains that share significant structural
similarities with modules and domains buried in ECM proteins
[69]. Among these, the disintegrin and disintegrin-like domains
found in snake venoms display a variety of integrin-binding motifs
with enormous pharmacological potential. Similar to the anti-
angiogenic fragments derived from mammalian ECMs, disintegrin
are also generated through proteolytic cleavage from larger
multidomain metalloproteases [70].
In this study, we show that a chimeric disintegrin, vicrostatin
(VCN), derived from a member of a well characterized family of
naturally occurring broad-spectrum integrin inhibitors, could be
successfully produced recombinantly in large scale in an
engineered bacterial system. The recombinant production of
VCN was a complex achievement complicated by the fact that
disintegrins are small polypeptides with almost no secondary
structure that depend for their proper folding and biological
activity on the correct pairing of a large number of disulfide
bridges (5 in VCN) relative to their molecular size. For this
reason, and because disintegrins do not express well in
mammalian cells or yeast, a bacterial system supportive of
disulfide bridge formation needed to be identified. We found that
VCN can be expressed in such a system (e.g., Origami B) which
prompted us to further optimize the expression method for this
recombinant polypeptide in this system. Our optimization efforts
led to consistent expression levels for this recombinant molecule
in Origami B with minimal batch-to-batch variation and with
yields around 200 mg of purified active VCN per liter of bacterial
culture. Recombinant VCN is a synthetic construct that retains
the RGD integrin-recognition motif displayed by the native
disintegrin contortrostatin (CN) it was derived from, but was also
engineered to exhibit some novel integrin biding characteristics.
Therefore, in a number of in vitro functional assays, recombinant
VCN was found to retain the binding properties of native CN,
while showing an improved binding affinity compared to native
CN for one important receptor in angiogenesis, integrin a5b1.
The binding affinity of VCN for integrin a5b1 was measured by
fluorescence polarization and found to be one order of magnitude
higher than that of CN (Kd=15.2 nM for VCN vs. 191.3 nM for
native CN). The recombinant VCN behaves like a true
disintegrin in that it inhibits platelet aggregation (by disrupting
fibrinogen binding to integrin aIIbb3) in a similar manner to
native CN and with a almost identical IC50 (approx. 60 nM).
Mass spectrometry analysis of VCN showed that this recombi-
nant disintegrin is, unlike CN, a monomer which led us to
speculate that VCN may have folded differently than CN in the
N-terminal half of the molecule and this prevented its
dimerization. Cell surface binding analyses by flow cytometry
conducted with fluorescently-labeled disintegrins showed that
VCN binds similarly to CN to different cell lines and, like CN, its
cell surface binding is abolished in the presence of integrin ligands
(either a cyclic RGD peptide or an antibody fragment) competing
for the same binding sites. Since disintegrin binding is a metal-ion
dependent process, we also showed that in the presence of metal
chelators both CN and VCN cease to bind to cells. The ability of
VCN to interfere with cell migration and invasion was further
tested in vitro in two experimental settings: in a modified Boyden
chamber using different cell lines (the transwell invasion assay)
and against HUVEC in the tube formation assay. In all instances
VCN was found to significantly inhibit cell migration and
invasion in the nanomolar range and with a potency similar to
that of native CN. Moreover, our previous studies indicated that
disintegrins are not cytotoxic to cells cultured in normal
conditions. In order to understand whether the anti-migratory/
anti-invasive effects observed with VCN were due to its ability to
interfere with essential components of cellular locomotor
apparatus (i.e., the dynamic actin cytoskeleton of migratory cells)
and was not the result of a cytotoxic effect, we conducted cell
viability studies with both CN and VCN using HUVEC and
cancer cells. Our results showed that both CN and VCN were
completely devoid of cytotoxicity at all concentrations tested (up
to 1 mM). Surprisingly, however, when HUVEC were sand-
wiched between two Matrigel layers, in an experimental setting
that allows these cells to move faster and form tubes more rapidly,
VCN did show a significant cytotoxic effect compared to other
integrin-targeting ligands tested (a cyclic RGD peptide and two
different antibodies). This effect was unexpected and suggests that
rapidly migratory and/or invasive cells might be the most
vulnerable to the effects of this agent. Our previous studies with
native CN indicate that this disintegrin may behave like a soluble
ECM-mimetic, potently altering the actin cytoskeleton dynamics
by deactivating key molecular components of focal adhesions in
both adherent HUVEC and glioma cells, the result of which is a
net anti-migratory effect [35]. Like native CN and unlike other
integrin-targeting ligands, we showed that VCN has a unique
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avb5, and a5b1) and is able to induce at nanomolar
concentrations the disassembly of actin stress fibers and a massive
actin cytoskeleton reorganization in HUVEC plated on Matrigel.
The ability of disintegrins to elicit an inappropriate signaling and
alter the tensional homeostasis in angiogenic and cancer cells
alike may have profound therapeutic implications since the
characteristic increase in tissue rigidity associated with cancers
was shown to critically modulate the behavior of malignant cells
by regulating the ability of these cells to form focal adhesions and
efficiently signal through growth factor receptors [71]. Further-
more, the ability to manipulate pharmacologically the actin
cytoskeleton and stress fiber assembly in transformed cells may
represent a novel therapeutic goal towards achieving tumor
dormancy [72,73]. Interestingly, the cytoskeletal effects observed
with VCN in tubulogenic EC cultured in a rich tumorigenic
matrix that is uniquely endowed to support both cell survival and
migration are strikingly similar to those exerted by the
endogenous ECM-derived fragments discussed above. As already
mentioned, these effects distinguish VCN from the other integrin
ligands that were tested in the same setting, including the small
cyclic RGD peptide cyclo(Arg-Gly-Asp-DPhe-Val). It is notewor-
thy to emphasize that a methylated variant of the cyclic RGD
peptide used in our experiments, the cyclo(Arg-Gly-Asp-DPhe-
NMeVal) peptide or Cilengitide, which displays an improved
specificity to integrins avb3a n davb5 [74,75], has been evaluated
in a number of advanced solid tumors in several clinical trials and
showed promise against glioblastoma multiforme [76,77]. More-
over, the two monoclonal antibodies that were included in our in
vitro assays, the integrin avb3-targeting 7E3 and LM609, were
also previously tested in vivo in a number of animal cancer models
and reported to have good tumor growth inhibition efficacy
[46,78]. By comparing different integrin ligands, our in vitro data
seem to indicate that molecules that behave like soluble ECM-
mimetics might have additional anti-angiogenic benefits com-
pared to cyclic RGD peptides and integrin-targeting monoclonal
antibodies. Furthermore, our results also suggest that, unlike
cyclic RGD peptides, VCN may produce effective anti-angio-
genic effects at much lower doses which may possibly translate
into fewer side effects.
Although VCN retains native CN’s ability to bind the activated
aIIbb3 platelet integrin, like CN [22] it does not interact with
quiescent platelets, an in vitro observation further corroborated by
our in vivo findings: no side effects were documented following
direct intravenous administration of purified VCN in two different
species: up to 1 mg per shot in mice or up to 5 mg per shot in rats.
It is important to mention that there is an established link between
activated platelets and metastasis [79,80] and from the therapeutic
standpoint it may be advantageous to use a polypeptide like VCN
that theoretically might also have the potential to address this
metastasis strategy. As a small polypeptide, VCN is not expected to
be immunogenic, and our preliminary animal studies showed that
VCN indeed failed to elicit an antibody response following
intravenous infusion. Despite these findings, for enhanced passive
targeting of the drug to the tumor site, we opted for liposomal
delivery. VCN can be efficiently encapsulated into unilamellar
liposomes, unlike other proteins possibly due to its structural
characteristics, and our findings indicate that the liposomal
formulations of VCN have far superior efficacy compared to the
naked polypeptide in two animal models of human cancer. In
these models LVCN showed excellent tumor growth inhibition
efficacy, increased animal survival and a significant reduction
(.80% compared to control) in tumor microvessel density
producing similar results compared to Avastin (bevacizumab).
Interestingly, in a separate study of the same breast cancer model
(MDA-MB-231 xenografts) VCN showed superior tumor apopto-
sis effects compared to Avastin as indicated by the quantitation of
the TUNEL-stained areas on tumor sections. As already
mentioned, in all these models the liposomal delivery of VCN
was far more efficacious compared to the intravenous administra-
tion of the naked polypeptide. We do not exclude, however, the
therapeutic scenario in which the naked polypeptide administered
at much higher doses than those used in this study might show
improved therapeutic responses. On the other hand, the liposomal
delivery has a number of other advantages showing good
therapeutic responses at lower drug doses and less frequent
administrations. To better understand how VCN is released from
liposomes in the tumor microenvironment, we are currently
conducting mechanistic studies aimed at elucidating the fate of
LVCN in tumor-bearing animals. As a unique broad-spectrum
anti-invasive drug, VCN may hold an advantage over other anti-
tumor therapeutic modalities in that it may be better suited to
address the cell survival loops operating in the avascular tissue in
the early steps of angiogenesis and metastasis [81,82]. For
instance, in an elegant animal study, Carbonell et al. [83] recently
demonstrated the critical importance of interactions between the
b1 integrin receptors on tumor cells and the vascular basement
membrane in maintaining the viability of early metastatic seeds in
the brain before the angiogenesis process is initiated. Moreover,
recent studies have demonstrated that the use of various anti-
VEGF/PDGF strategies is linked to an increased risk of early
metastasis in animal cancer models [84,85]. Although the clinical
relevance of these preclinical studies is not yet clear [86], these
data support the idea that not only is there an imperative need to
design novel anti-angiogenic drugs with better anti-invasive
properties, but also to test the impact of established anti-
angiogenics (such as Avastin) on metastasis and/or postoperative
survival when administered in combination with anti-invasive
modalities. In our previous studies conducted with native CN we
showed that this agent was very effective at blocking metastasis in
an animal model [87]. To better understand the ability of VCN to
function as an anti-metastatic agent, we are currently testing this
agent in several spontaneous models of breast cancer metastasis
(i.e., the murine 4T1 and D2F2, and human MDA-MB-231). In
summary, we believe that the novel agent described in this report
holds a promising translational potential and has a design
advantage over endogenous anti-angiogenic fragments in that it
can be made recombinantly in large quantities, safely infused into
animals, and efficiently encapsulated into liposomes for enhanced
tumor delivery.
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